Medtronic Community

NYSE:MDT Community

3 Narratives written by author
5 Comments on narratives written by author
165 Fair Values set on narratives written by author

EV

Community Contributor

Medtronic Stock: A Compelling Buy for Value and Income Investors as Robotics, Innovation Catalysts Ignite Upside to $105+

Strengths and Competitive Advantages: Diverse Product Portfolio: Medtronic operates across four key segments—Cardiovascular, Medical-Surgical, Neuroscience, and Diabetes—providing revenue stability and reducing dependency on any single product line. This diversification surpasses more specialized competitors like Boston Scientific (focused on cardiovascular) or Intuitive Surgical (robotics).

US$95.00

FV

12.7% undervalued

5.15%

Revenue growth p.a.

10

0

21

about 2 months ago

NA

Community Contributor

MDT Market Outlook

Medtronic plc (NYSE: MDT) is a leading medical device company with a diverse product portfolio and a strong global presence. As of January 4, 2025, the stock is trading at approximately $80.95 per share.

US$82.66

FV

0.3% overvalued

4.58%

Revenue growth p.a.

0

0

4

3 months ago

AN

AnalystConsensusTarget

Consensus Narrative from 27 Analysts

Medicare Approval Of RDN Technique Will Strengthen Future Prospects

Key Takeaways Expansion in PFA technology and the Hugo robotic platform are key drivers of Medtronic’s future growth, offering significant revenue opportunities. Strategic focus on emerging markets and new technologies like RDN is expected to boost revenue, market share, and operational efficiency.

US$96.94

FV

14.5% undervalued

4.71%

Revenue growth p.a.

1

0

101

4 days ago